Outcomes of Patients on Home Oxygen Undergoing Transcatheter Aortic Valve Replacement

Abstract

Home oxygen use can confer significant mortality risk for cardiac surgery patients. Transcatheter aortic valve replacement (TAVR) is an important option for patients with aortic stenosis on home oxygen. However, post-TAVR outcomes for these patients have not been thoroughly investigated. A single-center retrospective study of all patients on home oxygen who underwent TAVR between 2014 and 2023 was conducted. Primary outcomes included 60-day, 1-year, and 5-year mortality, and postprocedural change in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score. The final study population included 64 patients. Mortality rates at 60 days, 1 year, and 5 years were 7.8, 23.8, and 85.4%, respectively. KCCQ-12 summary score and all subscores increased between preprocedural screening and 1-year follow-up. Patients surviving beyond 5 years and experiencing improvement in KCCQ-12 score were more likely to have a higher body mass index and less severe chronic lung disease. Only 16.4% of patients were off home oxygen or had decreased oxygen requirements at 1 year. Although patients on home oxygen undergoing TAVR have high mortality rates, their long-term mortality is comparable to overall life expectancy for patients on home oxygen. TAVR can often confer increased quality of life for select patients on home oxygen. However, patients should be counseled on the high risk of morbidity and mortality, and expectations should be set regarding the low likelihood of decreasing oxygen requirements following TAVR.

Keywords

transcatheter aortic valve replacement - heart valve diseases - aortic valve stenosis - chronic obstructive pulmonary disease - respiratory tract diseases - patient-reported outcome measures - risk factors

Publikationsverlauf

Eingereicht: 05. Januar 2026

Angenommen: 14. Januar 2026

Artikel online veröffentlicht:
02. Februar 2026

• References

• 1 Khan AA, Murtaza G, Khalid MF, Khattak F. Risk stratification for transcatheter aortic valve replacement. Cardiol Res 2019; 10 (06) 323-330
• 2 Nathaniel S, Saligram S, Innasimuthu AL. Aortic stenosis: an update. World J Cardiol 2010; 2 (06) 135-139
• 3 Patail H, Kompella R, Hoover NE. et al. In-hospital and one-year outcomes of transcatheter aortic valve replacement in patients requiring supplemental home oxygen use. Cardiol Res 2023; 14 (03) 228-236
• 4 Lauridsen MD, Valentin JB, Strange JE. et al. Mortality in patients with chronic obstructive pulmonary disorder undergoing transcatheter aortic valve replacement: the importance of chronic obstructive pulmonary disease exacerbation. Am Heart J 2023; 262: 100-109
• 5 Society of Thoracic Surgeons, American College of Cardiology. TAVR In-Hospital Mortality Risk Calculator. 2024
• 6 Pavlov N, Haynes AG, Stucki A, Jüni P, Ott SR. Long-term oxygen therapy in COPD patients: population-based cohort study on mortality. Int J Chron Obstruct Pulmon Dis 2018; 13: 979-988
• 7 Harrison AC, Robinson JF, Tu L, McDonald CF, Khor YH. Multidisciplinary care and prognosis in patients with COPD and interstitial lung disease prescribed long-term oxygen therapy. Respir Care 2022; 67 (06) 667-675
• 8 Doldi P, Steffen J, Orban M. et al. Clinical outcome following transcatheter aortic valve implantation in patients with chronic obstructive pulmonary disease. JACC Cardiovasc Interv 2022; 15 (11) 1188-1190
• 9 Madanat L, Jabri A, Hanson ID. et al. Obesity paradox in transcatheter aortic valve replacement. Curr Cardiol Rep 2024; 26 (09) 1005-1009
• 10 Kumar A, Sammour Y, Reginauld S. et al. Adverse clinical outcomes in patients undergoing both PCI and TAVR: analysis from a pooled multi-center registry. Catheter Cardiovasc Interv 2021; 97 (03) 529-539
• 11 Tezuka T, Higuchi R, Hagiya K. et al. Midterm outcomes of underweight patients undergoing transcatheter aortic valve implantation: insight from the LAPLACE-TAVR registry. JACC Asia 2022; 3 (01) 78-89
• 12 Catalano MA, Saba SG, Rutkin B. et al. Association between multimodality measures of aortic stenosis severity and quality-of-life improvement outcomes after transcatheter aortic valve replacement. Eur Heart J Qual Care Clin Outcomes 2022; 8 (02) 143-149
• 13 Nuche J, Ternacle J, Avvedimento M. et al. Incidence, predictors, and prognostic significance of impaired functional status early after transcatheter aortic valve replacement. Rev Esp Cardiol (Engl Ed) 2024; 77 (05) 396-407
• 14 Arnold SV, Spertus JA, Vemulapalli S. et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: a report from the STS/ACC transcatheter valve therapy registry. JAMA Cardiol 2017; 2 (04) 409-416